Abstract 1678
Background
Immune checkpoint inhibitors (ICIs) are beneficial in a subset of metastatic renal cell carcinoma (mRCC) patients. However, no biomarker has been shown to be useful to select which patient benefits and the role of programmed death-ligand 1 (PD-L1) expression on tumor samples is controversial.
Methods
We assessed the potential role of PD-L1 expression according to Cochrane Collaboration’s Guidelines. Search of randomized clinical trials (RCTs) comparing ICIs (monotherapy or in combination with other therapies) to standard of care (SoC) in mRCC patients was performed. Trials must have included subgroup analysis evaluating the selected outcomes (progression-free survival-PFS- and overall survival-OS-) in different subsets of patients according to PD-L1 expression on tumor samples. Hazard ratios (HR) with confidence intervals (CI) were used as the measure of efficacy between groups.
Results
A total of 3,720 patients (5 studies) were included (ICIs arm: 1,913 patients; SoC arm: 1,807 patients). Globally, PFS and OS results favored ICIs. Differential expression of PD-L1 on tumor samples could select a subset of patients who could benefit more in terms of PFS (those with higher levels; p-value for difference between subgroups: 0.003) but it did not seem to impact in OS results (p-value for difference: 0.29).Table: 129P
Value of PD-L1 expression as a predictive biomarker for ICIs. HR: Hazard ratio. CI: Confidence interval
Total population | High PD-L1 | Low PD-L1 | p-value for difference | |
---|---|---|---|---|
PFS | HR 0.72; 95% CI 0.58-0.90 | HR 0.63; 95% CI 0.51-0.77 | HR 0.96; 95% CI 0,79-1.16 | 0.003 |
OS | HR 0.69; 95% CI 0.61-0.78 | HR 0.64; 95% CI 0.54-0.77 | HR 0.73; 95% CI 0.62-0.87 | 0.29 |
Conclusions
PD-L1 could represent a biomarker to test PFS in clinical trials but its value for OS is less clear.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract